Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 14/20 | 0.73 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.54 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.54 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26264278 | 0.89 | SUCNR1 (0.72) | SUCNR1PRSS1TMPRSS15C3AR1 | |
| SCHEMBL26264358 | 0.88 | SUCNR1 (0.71) | SUCNR1PRSS1TMPRSS15C3AR1 | |
| SCHEMBL26263219 | 0.88 | SUCNR1 (0.61) | SUCNR1C3AR1MMP13MGAMGAA | |
| SCHEMBL26264363 | 0.88 | SUCNR1 (0.81) | SUCNR1PRSS1TMPRSS15C3AR1MMP13 | |
| SCHEMBL26264257 | 0.87 | SUCNR1 (0.69) | SUCNR1PRSS1TMPRSS15C3AR1 | |
| SCHEMBL26264282 | 0.86 | C3AR1 (0.66) | SUCNR1PRSS1TMPRSS15C3AR1 | |
| SCHEMBL26264373 | 0.84 | SUCNR1 (0.76) | SUCNR1PRSS1TMPRSS15C3AR1 | |
| SCHEMBL26264369 | 0.84 | SUCNR1 (1.00) | SUCNR1PRSS1TMPRSS15C3AR1 | |
| SCHEMBL26264366 | 0.84 | SUCNR1 (0.69) | SUCNR1PRSS1TMPRSS15C3AR1MMP13 | |
| SCHEMBL26264365 | 0.84 | SUCNR1 (0.65) | SUCNR1PRSS1TMPRSS15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183776-A2 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | SUCNR1 1/4885PRSS1 1822/4885TMPRSS15 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.